Reckitt Benkiser completes agreement with Bristol-Myers Squibb
Reckitt Benkiser has completed its agreement with Bristol-Myers Squibb Company (BMS), having received the necessary approvals.
Reckitt Benkiser has completed its agreement with Bristol-Myers Squibb Company (BMS), having received the necessary approvals.
As reported back in February, Reckitt signed a three-year collaboration agreement under which it will license a number of Latin American consumer health care brands from BMS.
According to the terms of the agreement, Reckitt will initially pay BMS $482m to enter into the arrangement which also includes personnel, supply contracts and an option to acquire legal title to the related intellectual property at the end of the collaboration period, based on business performance.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The company will have the option to purchase at the end of the three year period.
NR
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
Will bond vigilantes come for Donald Trump?
Bond vigilantes could make a comeback if Donald Trump follows through on some of his promised policies
By Simon Wilson Published
-
Is Donald Trump's re-election a wake-up call for Europe?
Donald Trump will turbocharge the US economy – and expose Europe's weakness
By Matthew Lynn Published